Treatment | With the eventa (n=29) | Without the event (n=42) | p-value |
---|---|---|---|
Initial PSL dose (mg/kg/day) at week 0, mean ± SD | 0.97 ± 0.15 | 0.72 ± 0.23 | <0.001 |
GC pulse at week 0, n (%) | 23 (79.3) | 11 (26.2) | <0.001 |
Additional GC pulse within 4 weeks, n (%) | 17 (58.6) | 0 | - |
Additional immunosuppressive drugs at the event of poor treatment outcome, n (%) | 24 (82.8) | 0 | - |
MTX, n (%) | 10 (34.5) | - | - |
CyA, n (%) | 4 (13.8) | - | - |
Tac, n (%) | 4 (13.8) | - | - |
TCZ, n (%) | 2 (6.9) | - | - |
MTX + TCZ, n (%) | 1 (3.4) | - | - |
CyA + TCZ | 3 (10.3) | - | - |